Abstract：
OBJECTIVE: To describe the clinical application and outcome of MicroPulse™ transscleral cyclophotocoagulation (MP-TSCPC) treatment in horses with glaucoma.
METHODS: Four client-owned horses with primary (n = 2) or secondary (n = 2) glaucoma.
METHODS: Horses were treated with MP-TSCPC under standing sedation with a minimum of 30 days of follow-up (range 30-1241 days). Affected eyes were treated with a 31.3% duty cycle and 3000 mW laser power for a total of 180 s. Data collected included signalment, pre- and post-procedure intraocular pressures (IOPs), laser settings, medications, complications, and repeat therapy.
RESULTS: Four horses (5 eyes) received at least one treatment with MP-TSCPC. Mean preoperative IOP was 44 mmHg (range 33-49 mmHg). The immediate mean postoperative IOP was 34 mmHg (4 eyes; range 19-55 mmHg). At 1 week, IOP was 38 mmHg (5 eyes; range 21-80 mmHg), at 2 weeks was 40 mmHg (3 eyes, range 17-80 mmHg), at 1 month was 35 mmHg (5 eyes; range 20-50 mmHg), at 3 months was 18 mmHg (2 eyes; range 14-21 mmHg), at 6 months was 35 mmHg (2 eyes; range 30-39 mmHg), and at >300 days was 24 mmHg (3 eyes; range 18-29 mmHg). Complications included corneal ulceration (n = 1 eye), uncontrolled IOP (n = 3 eyes), and need for repeat treatment (n = 2 eyes).
CONCLUSIONS: MP-TSCPC used with the above-described settings was unsuccessful in treating the majority of cases. Future studies should be targeted at primary glaucoma cases and with use of alternative laser settings.
METHODS: Four client-owned horses with primary (n = 2) or secondary (n = 2) glaucoma.
METHODS: Horses were treated with MP-TSCPC under standing sedation with a minimum of 30 days of follow-up (range 30-1241 days). Affected eyes were treated with a 31.3% duty cycle and 3000 mW laser power for a total of 180 s. Data collected included signalment, pre- and post-procedure intraocular pressures (IOPs), laser settings, medications, complications, and repeat therapy.
RESULTS: Four horses (5 eyes) received at least one treatment with MP-TSCPC. Mean preoperative IOP was 44 mmHg (range 33-49 mmHg). The immediate mean postoperative IOP was 34 mmHg (4 eyes; range 19-55 mmHg). At 1 week, IOP was 38 mmHg (5 eyes; range 21-80 mmHg), at 2 weeks was 40 mmHg (3 eyes, range 17-80 mmHg), at 1 month was 35 mmHg (5 eyes; range 20-50 mmHg), at 3 months was 18 mmHg (2 eyes; range 14-21 mmHg), at 6 months was 35 mmHg (2 eyes; range 30-39 mmHg), and at >300 days was 24 mmHg (3 eyes; range 18-29 mmHg). Complications included corneal ulceration (n = 1 eye), uncontrolled IOP (n = 3 eyes), and need for repeat treatment (n = 2 eyes).
CONCLUSIONS: MP-TSCPC used with the above-described settings was unsuccessful in treating the majority of cases. Future studies should be targeted at primary glaucoma cases and with use of alternative laser settings.
摘要：
目的：描述MicroPulse™经巩膜睫状体光凝（MP-TSPC）治疗马青光眼的临床应用和结果。
方法：四匹主养马患有原发性（n=2）或继发性（n=2）青光眼。
方法：马在站立镇静下接受MP-TSCPC治疗，至少随访30天（范围30-1241天）。受影响的眼睛用31.3％的占空比和3000mW的激光功率治疗180s。收集的数据包括信号，术前和术后眼压（IOP），激光设置,药物,并发症,和重复治疗。
结果：四匹马（5只眼）接受了至少一次MP-TSCPC治疗。术前平均IOP为44mmHg（范围33-49mmHg）。术后即刻平均IOP为34mmHg（4眼；范围19-55mmHg）。在1周，IOP为38mmHg（5眼，范围21-80mmHg），2周时为40mmHg（3眼，范围17-80mmHg)，1个月时为35mmHg（5只眼；范围20-50mmHg），3个月时为18mmHg（2眼；范围14-21mmHg），6个月时为35mmHg（2只眼；范围30-39mmHg），在>300天时为24mmHg（3眼；范围18-29mmHg）。并发症包括角膜溃疡（n=1眼），IOP失控(n=3只眼睛),需要重复治疗（n=2只眼）。
结论：与上述设置一起使用的MP-TSCPC无法成功治疗大多数病例。未来的研究应针对原发性青光眼病例，并使用替代激光设置。
方法：四匹主养马患有原发性（n=2）或继发性（n=2）青光眼。
方法：马在站立镇静下接受MP-TSCPC治疗，至少随访30天（范围30-1241天）。受影响的眼睛用31.3％的占空比和3000mW的激光功率治疗180s。收集的数据包括信号，术前和术后眼压（IOP），激光设置,药物,并发症,和重复治疗。
结果：四匹马（5只眼）接受了至少一次MP-TSCPC治疗。术前平均IOP为44mmHg（范围33-49mmHg）。术后即刻平均IOP为34mmHg（4眼；范围19-55mmHg）。在1周，IOP为38mmHg（5眼，范围21-80mmHg），2周时为40mmHg（3眼，范围17-80mmHg)，1个月时为35mmHg（5只眼；范围20-50mmHg），3个月时为18mmHg（2眼；范围14-21mmHg），6个月时为35mmHg（2只眼；范围30-39mmHg），在>300天时为24mmHg（3眼；范围18-29mmHg）。并发症包括角膜溃疡（n=1眼），IOP失控(n=3只眼睛),需要重复治疗（n=2只眼）。
结论：与上述设置一起使用的MP-TSCPC无法成功治疗大多数病例。未来的研究应针对原发性青光眼病例，并使用替代激光设置。
